Chronic myeloid leukaemia

Jorge Cortes, Carolina Pavlovsky, Susanne Saußele

Research output: Contribution to journalReview articlepeer-review

Abstract

Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy. Achieving this goal requires an adequate understanding of the patient's treatment goals, careful monitoring for the achievement of optimal response hallmarks, implementation of proper interventions according to the attainment of such endpoints, adequate recognition and management of adverse events, and acknowledgment of the relevance of comorbidities. Treatment with tyrosine-kinase inhibitors, once considered lifelong, has become terminable for at least some patients, and promising new agents are emerging for those whose disease does not respond to any of the multiple therapeutic options currently available. If these advances reach all patients with chronic myeloid leukaemia, cure might eventually become a reality in most instances.

Original languageEnglish (US)
Pages (from-to)1914-1926
Number of pages13
JournalThe Lancet
Volume398
Issue number10314
DOIs
StatePublished - Nov 20 2021

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Chronic myeloid leukaemia'. Together they form a unique fingerprint.

Cite this